ReviewJournal of nuclear medicine : official publication, Society of Nuclear Medicine2021
Production and Supply of α-Particle-Emitting Radionuclides for Targeted α-Therapy.
Review in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed.
- Evolutionary landscape and collaborative networks of global theranostic research in nuclear medicine: a visual bibliometric analysis.Nuclear medicine communications · 2026Article
- Impact of Bipyridine and Phenanthroline Incorporation into the Macropa Scaffold on Ba(II)/Ra(II) Chelation.Inorganic chemistry · 2026Article
- Molecular imaging and radioligand therapies in pheochromocytomas and paragangliomas.Endocrine-related cancer · 2026Review
- Precision theranostics in oncology: integrating antibody-drug conjugates, radioimmunotherapy, and immuno‑PET for adaptive cancer care.Discover oncology · 2026Review
- Highly Efficient Extraction ofAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Alpha and Beta Emitters in Translational Nuclear Medicine: Clinical Advances, Challenges, and Future Direction.International journal of molecular sciences · 2026Review
- Solving the limited availability of Astatine-211 from a European perspective: from production to the end user.EJNMMI radiopharmacy and chemistry · 2026Review
- Alpha Therapy Beyond TOC and TATE-Production, Quality Control, and In-Human Results for the SSTR2 Antagonist DOTA-LM3.Pharmaceuticals (Basel, Switzerland) · 2026Article
- RadioPharm: the database of radiopharmaceuticals.Nucleic acids research · 2026Article
- Future of radiotheranostics.BMJ oncology · 2026Review
- Radiopharmaceutical: An Update and Comparison of Preclinical Investigation Result of Alpha and Beta Emitter Radioisotope.Drug design, development and therapy · 2026Review
- Lead radionuclides for theranostic applications in nuclear medicine: from atom to bedside.Theranostics · 2026Review
- Chemical Tools to Characterize the Coordination Chemistry of Radionuclides for Radiopharmaceutical Applications.Chemical reviews · 2025Review
- Measurement ofACS omega · 2025Article
- Recommendations on the Clinical Application and Future Potential of α-Particle Therapy: A Comprehensive Review of the Results from the SECURE Project.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Comparison of scatter and partial volume correction techniques for quantitative SPECT imaging ofEJNMMI physics · 2025Article
- PSMA-Directed Theranostics in Prostate Cancer.Biomedicines · 2025Review
- Review
- Production and Supply of Raw Materials for Radiometals used in Radionuclide Imaging and Therapy in Korea.Nuclear medicine and molecular imaging · 2025Review
- Preclinical investigation of [European journal of nuclear medicine and molecular imaging · 2025Article
Corrections and comments
- Erratum issuedErrata.2022
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Encouraging results from targeted α-therapy have received significant attention from academia and industry. However, the limited availability of suitable radionuclides has hampered widespread translation and application. In the present review, we discuss the most promising candidates for clinical application and the state of the art of their production and supply. In this review, along with 2 forthcoming reviews on chelation and clinical application of α-emitting radionuclides,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.